To include your compound in the COVID-19 Resource Center, submit it here.

Transcending crystallography

One company's downsizing is another's opportunity to move downstream. Syrrx Inc. last week added Onyx Pharmaceuticals Inc.'s small molecule discovery program to its core high throughput crystallography technology as it aims to begin pushing out drug candidates sometime after next year.

With ONXX scaling back to stretch its money over a fewer

Read the full 518 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers